The effect of thyrocalcitonin and growth hormones on bone metabolism

The use of the hormone, thyrocalcitonin, has been shown to change the bone metabolism so that resorption is decreased and calcium increased. The growth hormone seems to add to bone mass and indirectly prevents resorption. The combination of growth hormone and calcitonin seems to cause an unusual amount of resorption. This research has shown that metallic endosteal blade implants are not automatically successful even in short spans with additional support from two abutment teeth. It is true that the type of occlusion of the squirrel monkey is different from that of man, but the prosthetic devices that were placed in these animals can be validly compared to similar devices placed in man. While the hygiene cannot be practiced effectively by the animal, the psychogenic and emotional problems of man offset this disadvantage. Also, the diet of the monkey is not as traumatic to a prosthesis as is man's. Two of the most important criteria for implant success have not proved satisfactory: (1) no pocket depth beyond 3 mm. and (2) negative radiographic pathosis around the implant. While this study was not meant to be one of criticism or evaluation of metallic implants, it should be noted that thyrocalcitonin and the growth hormone, individually used, played an important part in retarding bone resorption around the blade. Autogenous bone grafts for residual alveolar ridge restoration often fail due to rapid osseous resorption and volume loss. The maintenance of osseous elements in the autogenous bone grafts when calcitonin had been administered was quite revealing. This might be the chemotherapeutic basis for the many conditions involving bone that dentists are called upon to treat.